Search

Supplemental material, sj-docx-1-opp-10.1177_10781552211073885 for Non hemorrhagic pericardial effusion from ibrutinib ��n a patient without comorbidities by Burcu Aslan Cand��r, Tu����e Nur Yi��eno��lu, Merih K��z��l ��akar, Mehmet Sinan Dal and Fevzi Altunta�� in Journal of Oncology Pharmacy Practice

Supplemental material, sj-docx-1-opp-10.1177_10781552211073885 for Non hemorrhagic pericardial effusion from ibrutinib ��n a patient without comorbidities by Burcu Aslan Cand��r, Tu����e Nur Yi��eno��lu, Merih K��z��l ��akar, Mehmet Sinan Dal and Fevzi Altunta�� in Journal of Oncology Pharmacy Practice

Supplemental material, sj-docx-1-opp-10.1177_10781552211073881 for Skin ulcers caused by ruxolitinib in a patient with chronic cutaneous graft-versus-host disease by Burcu Aslan Cand��r, Tu����e Nur Yi��eno��lu, Merih K��z��l ��akar, Mehmet Sinan Dal and Fevzi Altunta�� in Journal of Oncology Pharmacy Practice

Supplemental material, sj-docx-1-opp-10.1177_10781552211073881 for Skin ulcers caused by ruxolitinib in a patient with chronic cutaneous graft-versus-host disease by Burcu Aslan Cand��r, Tu����e Nur Yi��eno��lu, Merih K��z��l ��akar, Mehmet Sinan Dal and Fevzi Altunta�� in Journal of Oncology Pharmacy Practice

The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP).A total of 285 chronic ITP patients (187 women, 65.6%; 98 men, 34.4%) followed in 55 centers were enrolled in this retrospective cohort. Response to treatment was assessed according to platelet count (/mmThe median age at diagnosis was 43.9±20.6 (range: 3-95) years and the duration of follow-up was 18.0±6.4 (range: 6-28.2) months. Overall response rate was 86.7% (n=247). Complete and partial responses were observed in 182 (63.8%) and 65 (22.8%) patients, respectively. Thirty-eight patients (13.4%) did not respond to eltrombopag treatment. For patients above 60 years old (n=68), overall response rate was 89.7% (n=61), and for those above 80 years old (n=12), overall response rate was 83% (n=10). Considering thrombocyte count before treatment, eltrombopag significantly increased platelet count at the 1Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors.Bu çalışmanın amacı kronik immün trombositopeni (ITP) hastalarında bir oral trombopoietin reseptör agonisti olan eltrombopagın etkinlik ve güvenirliliğini değerlendirmektir.Elli beş merkezde izlem altındaki toplam 285 kronik ITP hastası (187 kadın, %65,6) bu geriye dönük küme çalışmasına alınmıştır. Tedaviye yanıt trombosit sayısına göre değerlendirilmiş ve tam yanıt (100.000/mmTanı anında yaş ortalaması 43,9±20,6 (3-95) yıl olan hastalar ortalama 18,0±6,4 (6-28,2) ay izlenmiştir. Tam ve kısmi yanıtı içeren toplam yanıt %86,7 (n=247) bulundu. Sırasıyla 182 (%63,8) ve 65 (%22,8) hastada tam ve parsiyel tedavi yanıtları gözlenmiştir. Otuz sekiz hasta (%13,4) eltrombopag tedavisine yanıt vermemiştir. Altmış yaş üzerindeki hastalarda (n=68) toplam yanıt %89,7 (n=61) bulunurken, bu oran 80 yaş üzerindeki (n=12) hastalarda %83 (n=10) olmuştur. Tedavi öncesi trombosit sayısı göz önüne alındığında, eltrombopag, tedavinin 1., 2., 3., 4. ve 8. haftalarında trombosit sayısını anlamlı şekilde artırmıştır. Kısmi veya tam cevap için gereken süre arttıkça, tedaviye cevap önemli ölçüde azaldığı saptanmıştır. Eltrombopag tedavisinden sonra maksimum trombosit sayısı ne kadar yüksekse, yan etkilerin oluşabilme ihtimalinin o kadar yüksek olabildiği dikkati çekmiştir. En sık görülen yan etkiler baş ağrısı (%21,6), güçsüzlük (%13,7) ve hepatotoksisite (%11,8) ve trombozdur (%5,9).Mevcut çalışmanın sonuçları, eltrombopag tedavisinin kronik ITP’de, yaşlı hastalar dahil olmak üzere, etkili bir tedavi seçeneği olduğunu göstermektedir. Bununla birlikte, hastalar tedavi sırasında yanıt ve yan etkiler açısından yakından izlenmelidir. Hem cevap hem de yan etkiler, takip süresi boyunca değişken olabileceğinden, hastalar özellikle tromboz risk faktörleri açısından dinamik olarak değerlendirilmelidir.

Supplemental material, OPP879496 Supplemetal Material for Development of pneumonitis after rituximab treatment in a patient with lymphoma by Duygu Mert, Alparslan Merdin, Sabahat Ceken, Mehmet Sinan Dal, Mustafa Ertek and Fevzi Altuntas in Journal of Oncology Pharmacy Practice

In the present study, we investigated the relationship between serum TNF-α levels and hepatic activity in liver biopsies of chronic hepatitis B and C patients.The study was performed on 30 chronic hepatitis B patients, 25 chronic hepatitis C patients and 25 healthy controls. Serum samples of patients who underwent biopsy and healthy controls were collected. Control group was seronegative for hepatitis and had normal liver function tests. TNF- α levels measured by ELISA. Knodell’s hepatic activity index was used in evaluation of liver biopsies. Serum TNF-α levels were determined higher in chronic hepatitis B and C patients than control group. HAI and TNF- α compared in chronic hepatitis B and C patients. Although we detected a relationship between HAI and TNF-α levels in chronic hepatitis B patients, no true correlation was shown in chronic hepatitis C patients. Cytokines have an important role in progression of chronic hepatitis B and C infections. There is a relationship between hepatic activity index and TNF-α level in chronic hepatitis B infection.But There is not relationship between hepatic activity index and chronic hepatitis C infection.only in two patients and both of them where in the middle of their reproductive age while as symptomatic ovarian cysts was a more common finding in unmarried females in 21-28 years of age group. This study concluded that laparoscopy has a diagnostic as well as a therapeutic implication in management of NSAP. Keywords: Hepatic activity index, serum tumor necrosis factor alpha, chronic active hepatitis-b, chronic active hepatitis-c

Prolymhocytic leukemia (PLL) is a rare subtype of lymphocytic leukemias and its cells are immature lymphocytes. It is divided into 2 subgroups: T-PLL and B-PLL according to the lymphocytic origin of the cells. Discriminating B-PLL from other diseases with clinically-similar features is important because of the different treatment approaches and follow-up programs. Hereby, we report a 80-year-old woman presenting with fatigue, leucocytosis and mild anemia. Her peripheral blood smear evaluation revealed 85% prolymphocytes with moderately condensed nuclear chromatin, prominent nucleoli, and a faintly basophilic cytoplasm. Positron emission tomography-computed tomography showed mediastinal lymph nodes with cervical lymph nodes. There was no pathological FDG involvement in the spleen. Bone marrow aspiration smear exhibit atypical wide lymphocytes with prominent nucleoli and abundant agranular cytoplasm. Flow cytometry analysis revealed positive CD5+, CD19+, CD20+, CD22+, CD11c+, CD25+, CD79a+ and CD79b+. Fluorescence in situ hybridization technique analysis reveals no t(11;14). Bone marrow biopsy revealed interstitially distributed atypical cells with wide nucleus and prominent nucleolus.

This study investigates Turkeys’ greenhouse gases, economicgrowth and energy consumption relations by using 1960-2010 data for the relatedindicators. For this purpose, Dynamic Ordinary Least Squares method wasdeveloped. Ampirical results does not support Environmental Kuznets Curvehypothesis, which suggest the relationship between the income per capita andcarbondioxide emissions are inverted U-shaped. Our results have found invertedN-shaped relationship between these two variables. The results also found asignificant and positive relationship between energy consumption and ghgemissions., Bu çalışma, Türkiye’de ekonomik büyüme, enerjitüketimi ve sera gazı emisyonları arasındaki ilişki 1960-2010 dönemiverileriyle incelenmiştir. Bu ilişki Dinamik En Küçük Kareler yöntemiyle araştırılmıştır.Çalışmada, literatürde tartışılan ters U şeklindeki Çevresel Kuznets Eğrisi’ninolmadığı, kişi başı karbon emisyonları ile kişi başı gelir arasında ters Nşeklinde bir ilişki olduğu ampirik analiz sonucunda elde edilmiştir. Ayrıca,Enerji tüketiminin katsayısının pozitif ve anlamlı olması beklentilerle uyumluolarak gerçekleşmiştir.

PNH Education and Study Group ( PESG) have been established in December 2013 as a non-profit, independent, medical organization www.pesg.org. Paroxysmal Nocturnal Hemoglobinuria ( PNH) is a multi-systemic disease that should be treated with a multidisciplinary approach. Patients may apply to the clinics other than the hematology due to variability and diversity of clinical findings which lower the rate of diagnosis due to low awareness about PNH. PNH might be overlooked and diagnosis might be delayed. Regarding these, PESG was established with the collaboration of Immunology, Cardiology, Thorax Diseases ( Pulmonology), Neurology, Gastroenterology, General Surgery and Urology specialists in addition to hematologists dealing with PNH. The PESG study group aims to increase the awareness about PNH, including training activities about PNH, strengthening the relations between clinics and planning of clinical studies as a goal. It is the first professional organization focusing on PNH, in Turkey. In this guideline, we want to facilitate the diagnosis attributes of physicians from all specializations that deal with PNH and its systemic complications. One can perceive this as a tailor made guideline of international guidelines but not a compilation.

WOS: 000425633300017, PubMed ID: 28707314, Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses.